|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our results unraveled a novel regulatory of GSK3β by PCNA and provided a promising direction for treatment of lung cancer.
|
31607135 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In breast cancer, alterations in the cell cycle and uncontrolled proliferation led to several studies interrogating the relationship between cyclins and their counterpart cyclin-dependent-kinases (CDKs).
|
31481582 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on immunohistochemical observations of proliferating cell nuclear antigen (PCNA) and platelet/endothelial cell adhesion molecule-1 (PECAM-1 or CD31) results, we concluded the CL-induced y-CDs-Ce6 system had excellent performance in cancer therapy, the enhanced therapeutic effect was ascribed to two pathways: a direct CRET process, and another process of CRET with subsequent y-CD-mediated FRET (CRET-to-FRET).
|
31830411 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The knockdown of SPOCK1 significantly decreased the proliferation and metastasis of PCNA-1 and MIA PaCa-2 cells.
|
31478239 |
2020 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In breast cancer, alterations in the cell cycle and uncontrolled proliferation led to several studies interrogating the relationship between cyclins and their counterpart cyclin-dependent-kinases (CDKs).
|
31481582 |
2020 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results unraveled a novel regulatory of GSK3β by PCNA and provided a promising direction for treatment of lung cancer.
|
31607135 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on immunohistochemical observations of proliferating cell nuclear antigen (PCNA) and platelet/endothelial cell adhesion molecule-1 (PECAM-1 or CD31) results, we concluded the CL-induced y-CDs-Ce6 system had excellent performance in cancer therapy, the enhanced therapeutic effect was ascribed to two pathways: a direct CRET process, and another process of CRET with subsequent y-CD-mediated FRET (CRET-to-FRET).
|
31830411 |
2020 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results unraveled a novel regulatory of GSK3β by PCNA and provided a promising direction for treatment of lung cancer.
|
31607135 |
2020 |
|
Esophageal carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We found that miR-196a knockdown or PKC inhibition by sotrastaurin changed PKC expression which then reduced esophageal cancer cell proliferation and downregulated proliferating cell nuclear antigen expression via the classical B-cell receptor-PKC nuclear factor-κB pathway but not the alternative pathway; in addition, miR-196a inhibition can increase the caspase level and induce esophageal cancer cell apoptosis.
|
31743132 |
2020 |
|
Malignant neoplasm of esophagus
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We found that miR-196a knockdown or PKC inhibition by sotrastaurin changed PKC expression which then reduced esophageal cancer cell proliferation and downregulated proliferating cell nuclear antigen expression via the classical B-cell receptor-PKC nuclear factor-κB pathway but not the alternative pathway; in addition, miR-196a inhibition can increase the caspase level and induce esophageal cancer cell apoptosis.
|
31743132 |
2020 |
|
Esophageal Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We found that miR-196a knockdown or PKC inhibition by sotrastaurin changed PKC expression which then reduced esophageal cancer cell proliferation and downregulated proliferating cell nuclear antigen expression via the classical B-cell receptor-PKC nuclear factor-κB pathway but not the alternative pathway; in addition, miR-196a inhibition can increase the caspase level and induce esophageal cancer cell apoptosis.
|
31743132 |
2020 |
|
Fanconi Anemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
SMI#9 attenuated cisplatin-induced PCNA monoubiquitination (TLS marker), FANCD2 (Fanconi anemia (FA) activation marker), and TLS polymerase POL η. SMI#9-induced decreases in γH2AX levels were associated with concomitant inhibition of H2AX monoubiquitination, suggesting a key role for RAD6 in modulating cisplatin-induced γH2AX via H2AX monoubiquitination.
|
31639439 |
2020 |
|
FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)
|
0.050 |
Biomarker
|
disease |
BEFREE |
SMI#9 attenuated cisplatin-induced PCNA monoubiquitination (TLS marker), FANCD2 (Fanconi anemia (FA) activation marker), and TLS polymerase POL η. SMI#9-induced decreases in γH2AX levels were associated with concomitant inhibition of H2AX monoubiquitination, suggesting a key role for RAD6 in modulating cisplatin-induced γH2AX via H2AX monoubiquitination.
|
31639439 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In addition, nesfatin-1 treatment upregulated the PCNA and Bcl2 expression and inhibited the caspase-3 and prohibitin expression in T2DM mice.
|
31691259 |
2020 |
|
Cataract
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Purpose</b>: This study aims to determine the expression patterns of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), proliferating cell nuclear antigen (PCNA) and SOX2 in lens epithelial cells (LEC) of cataract patients with pseudoexfoliation syndrome (PEX), and to determine the effect of apoptosis, proliferative activity and stem/progenitor cells on cataract formation in patients with PEX.
|
31424957 |
2020 |
|
Congenital diaphragmatic hernia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Nitrofen was administered orally to establish a rat CDH model, and pathological changes were evaluated through hematoxylin-eosin (H&E), PCNA, and Ki67 staining at the pseudoglandular stage.
|
31734580 |
2020 |
|
Skin callus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TLR4 knockout promoted fracture healing, reduced the number of osteoclasts, increased bone callus volume (BV) and callus mineralized volume fraction (BV/TV%) (P < 0.05), increased the maximum torque and torsional stiffness of callus (P < 0.05), reduced TNF-α, IL-1β and IL-6 expression (P < 0.01), and increased the expression levels of β-catenin, Wnt4, Wnt5B, PCNA and BMP-2 (P < 0.01).
|
31796334 |
2020 |
|
Necrotizing enterocolitis in fetus OR newborn
|
0.020 |
Biomarker
|
disease |
BEFREE |
Similarly, expression of proliferation markers of Ki67 and PCNA was lower in NEC liver organoids.
|
31365937 |
2020 |
|
Exfoliation Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Purpose</b>: This study aims to determine the expression patterns of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), proliferating cell nuclear antigen (PCNA) and SOX2 in lens epithelial cells (LEC) of cataract patients with pseudoexfoliation syndrome (PEX), and to determine the effect of apoptosis, proliferative activity and stem/progenitor cells on cataract formation in patients with PEX.
|
31424957 |
2020 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In order to explore the application value of DCE-MRI in clinical diagnosis and treatment, guide early clinical diagnosis, evaluate prognosis, guide clinical selection of treatment options and improve medical level, the expression of adenocarcinoma, its relationship with clinicopathology, and the significance of co-expression of the proliferating cell nuclear antigen (PCNA), Ki67 protein and cyclooxygenase 2 (COX-2) in breast cancer are analyzed.
|
31289003 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that targeting PCNA with PCNA-I1S may provide a novel approach for enhancing the efficacy of chemotherapy and radiation therapy in treatment of human prostate and lung cancer.
|
31600334 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reverse transcription quantitative polymerase chain reaction analysis revealed that PCNA‑1 was significantly upregulated (up to 5‑fold) in the lung cancer cells (P<0.05), and the overexpression of miR‑204 caused the downregulation of PCNA‑1 in A549 lung cancer cells.
|
30628638 |
2019 |
|
Lung Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
We show this association of PRPRT methylation with upregulation of the STAT3 target genes <i>Cyclin D1</i> and <i>Bcl-X<sub>L</sub></i> in patient derived lung tumour samples.
|
31595832 |
2019 |
|
Psoriasis
|
0.330 |
Biomarker
|
disease |
BEFREE |
White mange mixture can significantly inhibit vaginal psoriasis in a mouse model by decreasing the amount of epithelium KC cell PCNA and production of the inflammatory cytokines GM-CSF in serum.
|
31384318 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functionally, PCNAP1 or PCNA remarkably enhanced HBV replication and accelerated the growth of HCC <i>in vitro</i> and <i>in vivo</i>.
|
31410212 |
2019 |